



Identification of novel ER-alpha target genes in breast
cancer cells: Gene- and cell-selective co-regulator
recruitment at target promoters determines the
response to 17beta-estradiol and tamoxifen
Citation for published version (APA):
Romano, A., Michiel Adriaens, M. E., Kuenen, S., Delvoux, B., Dunselman, G., Evelo, C., & Groothuis, P.
(2010). Identification of novel ER-alpha target genes in breast cancer cells: Gene- and cell-selective co-
regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen.
Molecular and Cellular Endocrinology, 314(1), 90-100. https://doi.org/10.1016/j.mce.2009.08.008





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.





































Molecular and Cellular Endocrinology 314 (2010) 90–100
Contents lists available at ScienceDirect
Molecular and Cellular Endocrinology
journa l homepage: www.e lsev ier .com/ locate /mce
dentification of novel ER- target genes in breast cancer cells: Gene- and
ell-selective co-regulator recruitment at target promoters determines
he response to 17-estradiol and tamoxifen
ndrea Romanoa,b,∗, Michiel Adriaensc, Sabine Kuenena,b, Bert Delvouxa,b,
erard Dunselmana,b, Chris Eveloc, Patrick Groothuisa,b,1
GROW, School for Oncology and Developmental Biology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands
Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands
Department of Bioinformatics - BiGCaT, Maastricht University Medical Centre, 6202 AZ Maastricht, The Netherlands
r t i c l e i n f o
rticle history:
eceived 15 April 2009
eceived in revised form 12 August 2009




a b s t r a c t
Tamoxifen and 17-estradiol are capable of up-regulating the expression of some genes and down-
regulate the expression of others simultaneously in the same cell. In addition, tamoxifen shows distinct
transcriptional activities in different target tissues.
To elucidate whether these events are determined by differences in the recruitment of co-regulators by
activated estrogen receptor- (ER-) at target promoters, we applied chromatin immunoprecipitation
(ChIP) with promoter microarray hybridisation in breast cancer T47D cells and identified 904 ER- targets
genome-wide. On a selection of newly identified targets, we show that 17-estradiol and tamoxifen stim-o-activators
o-repressors
amoxifen
ulated up- or down-regulation of transcription correlates with the selective recruitment of co-activators
or co-repressors, respectively. This is shown for both breast (T47D) and endometrial carcinoma cells
(ECC1). Moreover, differential co-regulator recruitment also explains that tamoxifen regulates a number
of genes in opposite direction in breast and endometrial cancer cells. Over-expression of co-activator
SRC-1 or co-repressor SMRT is sufficient to alter the transcriptional action of tamoxifen on a number of
targets. Our findings support the notion that recruitment of co-regulator at target gene promoters and
termtheir expression levels de
. Introduction
Upon ligand activation, estrogen receptor- (ER-) binds to the
romoters of responsive genes, interacting directly with estrogen
esponse elements (EREs) or indirectly via associations with other
ranscription factors (reviewed in: Lonard and O’Malley, 2007).
umerous mechanisms participate in the fine-tuning of estrogen
egulatory actions in target cells. These mechanisms allow estro-
ens and selective estrogen receptor modulators (SERMs) to exert
pposite transcriptional actions on different genes in the same cell
ype, or to act as agonists in one cell type and as antagonists in
nother cell type. However, they may also be responsible for the
nwanted side effects that have been observed during the use of
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oi:10.1016/j.mce.2009.08.008ine the effect of ER- on gene expression to a large extent.
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these compounds in medical treatments. The SERM tamoxifen, for
instance, acts as an ER- antagonist in breast cancer cells (Conzen,
2008; Riggs and Hartmann, 2003), but it is a partial agonist in the
endometrium and increases the incidence of endometrial hyper-
plasia and cancer (Gielen et al., 2005; Shang, 2006). In addition,
the same mechanisms may play a role in the resistance to tamox-
ifen of breast tumours (Conzen, 2008; Lonard et al., 2007) and in
the patient-dependent therapeutic efficacy of tamoxifen for the
treatment of ovarian cancer (Perez-Gracia and Carrasco, 2002).
There is increasing evidence that the gene- and cell-specific
actions of estrogens depend largely on the presence of co-
regulators. These proteins either bridge the ER-/target promoter-
complex with the transcriptional machinery (co-activators such as
CBP, p300, SRC family) or impair it (co-repressors; SMRT, NCoR;
Carroll and Brown, 2006; Lonard and O’Malley, 2007). Several
recent studies have indicated that the agonistic or antagonistic
action of a SERM is determined by the cellular availability of co-
regulators in different cell types. For instance, the agonistic action
of tamoxifen in endometrial cancer cells is the consequence of high
expression of the co-activator SRC-1 (Shang and Brown, 2002). In
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amoxifen into an inducer of proliferation and over-expression of
o-activator SRC-3 (AIB1) is predictive of resistance to tamoxifen
n breast cancer patients and is associated with malignancies in
he endometrium (Balmer et al., 2006; Conzen, 2008; Lonard et al.,
007).
Despite these evidences, the direct effect of co-regulators on
R--controlled gene transcription in distinct cell types has been
emonstrated for a limited number of targets only (Shang and
rown, 2002; Shang et al., 2000; Stossi et al., 2006) or by means
f reporter gene assays (Peterson et al., 2007; Smith et al., 1997). In
ddition, it remains difficult to understand how estrogens induce
he expression of specific genes and repress others in the same cell
ype (Bourdeau et al., 2008; Carroll et al., 2006; Hodges et al., 2003;
won et al., 2007; Lin et al., 2004, 2007a,b; Groothuis et al., 2007).
In the present study, we aimed at examining whether
ifferential co-regulator recruitment (i) determines different tran-
criptional actions of one ligand on distinct target genes in the same
ell type and (ii) determines the opposite transcriptional regulation
f the same genes in different cell types treated with the same lig-
nd. To this end, we applied chromatin immunoprecipitation (ChIP)
ogether with promoter DNA array hybridisation (ChIP-chip) and
dentified 904 ER- target promoters in T47D breast cancer cells.
n a selection of newly identified target genes, we show that the
ranscriptional stimulatory or inhibitory effects of 17-estradiol or
H-tamoxifen, the active metabolite of tamoxifen, closely correlate
ith the recruitment of co-activators or co-repressors, respectively.
oreover, recruitment of distinct co-regulators correlates with the
pposite transcriptional responses observed in T47D and endome-
rial cancer cells (ECC1). To further support this notion, we show
hat over-expression of co-activator SRC-1 or co-repressor SMRT is
ufficient to change or to invert OH-tamoxifen response, irrespec-
ive to the cell context.
. Materials and methods
.1. Cell lines and culture
The human breast cancer cell line T47D and human endometrial cancer cell line
CC1 were purchased from the American Type Culture Collection (ATCC; Rockville,
D, USA) and maintained as described (Romano et al., 2007). For all experiments
nvolving hormonal stimulation, cells were cultured for five days prior to, and
uring the experiment in RPMI without phenol-red (Invitrogen, Life Technologies,
nc., Carlsbad, CA) supplemented with 5% hormone-stripped serum (c.c.pro GmbH,
eustadt, Germany).
.2. Steroid hormones
17-estradiol and OH-tamoxifen were purchased from Sigma–Aldrich Chemie
V (Zwijndrecht, The Netherlands). ICI-164384 was a gift from Schering-Plough (Oss,
he Netherlands).
.3. RNA extraction and cDNA synthesis
RNA was isolated using the Trizol reagent (Invitrogen, Life Technologies, Inc.,
arlsbad, CA) as recommended by the manufacturer. Complementary DNA (cDNA)
as synthesised using the M-MLV reverse transcriptase (Invitrogen, Life Technolo-
ies, Inc., Carlsbad, CA) as described earlier (Romano et al., 2007).
.4. Oligonucleotides
Oligonucleotides used for linear-amplification of immunoprecipitated chro-
atin prior to ChIP-chip and used for PCR were purchased from MWG-Biotech AG
Ebersberg, Germany) and are listed in Supplemental Table S-III.
.5. PCR and real-time PCR (RT-PCR)PCR was performed with the Taq DNA polymerase (Fermentas GMBH, St Leon-
ot, Germany) as recommended by the manufacturer. Semi-quantitative PCR was
erformed by stopping PCR reactions every three cycles and by evaluation of band
ntensity on an agarose gel. RT-PCR was performed using the Syber-green ABGene
ystem (ABGene Limited, Epsom, United Kingdom), as recommended by the manu-
acturer and the BioRad MyIQ apparatus.Endocrinology 314 (2010) 90–100 91
2.6. Chromatin immunoprecipitation
ChIP was performed as described elsewhere (Romano et al., 2007). Briefly, T47D
or ECC1 cells were grown to 80% confluence (165-cm2 culture flasks) treated with
vehicle only (ethanol) or with ligand for 50 min, fixed (1% formaldehyde, 10 min)
and scraped in 1 ml of cold PBS supplemented with CompleteTM protease inhibitor
(Roche, Mannheim, Germany). After cell lysis, nuclei were pelleted, lysed and chro-
matin was sonicated. Chromatin-protein complexes were immunoprecipitated (IP)
with protein-G/A magnetic beads (Dynal, Invitrogen Life Technologies, Inc., Carlsbad,
CA) and 2 g of specific antibodies: HC-20 against ER-, H-224 against RNA-Pol-II,
C-20, N-15 and A-22 against co-activators SRC-1, p300 and CBP, and antibodies sc-
1609 and H-300 against co-repressors NCoR and SMRT (Santa Cruz Biotechnology,
CA, USA). After IP, bead washing and reverse crosslinking, DNA was purified using
the Qiaquick reaction clean-up kit (Qiagen GmbH, Hilden, Germany). Binding of the
RNA-Pol-II to the GAPDH promoter was used as positive control of the ChIP pro-
cedure and it was assessed using primers ChIP-positive (Supplemental Table S-III).
ER- binding to the TFF1 promoter was used as a positive control for ChIP with the
ER- antibody and it was assessed using primers indicated in Supplemental Table
S-III. ChIP PCR signals were normalised with an unspecific negative control, using
primers ChIP-negative (Supplemental Table S-III) that flank the cytogenetic location
12p13.3 where no transcription factors bind. All additional primers used to assess
ER- and co-regulatory protein binding are listed in Supplemental Table S-III.
2.7. ChIP-chip
ChIP in T47D cells using the ER- antibody was performed as described above.
Successful ChIP was confirmed by assessing ER- binding to the promoter of the
estrogen responsive gene TFF1. Isolated DNA fragments were subsequently sub-
jected to a linear-amplification as follows: (a) 7.5 l of DNA were denatured,
amplified with 1.5 U of SequenaseTM T7 DNA-polymerase (Invitrogen, Life Tech-
nologies, Inc., Carlsbad, CA) using primer LA-0 (Supplemental Table S-III) in the
recommended buffer (1X) for 8 min at 37 ◦C. This step was repeated once. (b) 15 l
of this reaction were amplified by Taq polymerase (Fermentas GMBH, St Leon-Rot,
Germany) using primer LA-1 (Supplemental Table S-III) in 0.1 mM dNTPs, 1X rec-
ommended buffer, 1.5 mM MgCl2 in 100 l final volume. Aliquots (5 l) were taken
at 25, 30, 35, 40 cycles to determine the number of cycles necessary to enter the
exponential phase (which was determined based on the intensity of the smeared-
DNA visualised on an agarose gel). A second round of amplification using the Taq
polymerase was performed. Amplified DNA was purified using the Qiaquick reaction
clean-up kit (Qiagen GmbH, Hilden, Germany). Enrichment of the TFF1 promoter was
confirmed at intermediate steps of the amplification and at the end of the amplifica-
tion (Fig. 1A). This quality control guaranteed that the amplification of signals in the
ChIP-DNA did not reach saturation and therefore did not result in loss of enrichment
of target promoters.
Samples were generated from three independent experiments (T1, T2 and T3).
In each experiment, cells were treated with 17-estradiol or vehicle for 50 min. In
addition, a reference pool (P) was created by pooling equal amounts of the ampli-
fied DNA from the 17-estradiol and vehicle-treated samples of T1, T2 and T3. The
ChIP-DNA fraction was labelled with Cy-5, while the input-DNA, the DNA purified
from fragmented chromatin non-subjected to IP reaction and processed through the
same linear-amplification as the ChIP-DNA, was labelled with Cy-3. Labelled ChIP-
and input-DNA fractions from the eight samples (four treated and four untreated)
were subsequently hybridised to the Nimblegen HGS17 genome build promoter
microarray containing 1500 bp of promoters from 24,134 human genes. Labelling
and hybridisation were performed in-house by Nimblegen (Madison, USA). The pro-
moter regions on the array are covered by 50- to 75-mer probes with approximately
100 bp spacing. The log-ratio of Cy-5 and Cy-3 intensities was subsequently calcu-
lated to assess enrichment of specific promoters of the ChIP-DNA compared to the
input-DNA, suggesting binding of ER-. The hybridisation efficiency of the sam-
ples from experiment T3 did not meet the quality criteria and these samples were
excluded from further analysis.
2.8. Statistical analysis
Two different methods were evaluated for the identification of ER- targets.
Method (i), a within-array analysis, searches for four or more probes in each 1500 bp
promoter whose signals are above a specified cut-off value. This analysis was
performed using the proprietary software of Nimblegen. Method (ii) is a between-
array analysis, employing positive (treated replicate samples) and negative controls
(vehicle-treated samples) at probe level, which was performed in the statistical pro-
gramming language R. This latter method is expected to produce a statistically more
robust set of potential ER- targets. First, the log-ratio between ChIP-DNA and input-
DNA intensities is calculated separately for each array. Next, all probes are ordered
according to genomic location and dichotomised using a threshold around twice the
estimated standard deviation of the log-ratio. Probes with log-ratio values above this
threshold are designated as positive, those below the threshold negative. Next, for
each array, a sliding window of a variable number of base pairs is moved over all
probes, calculating a p-value for each window with a Yates corrected chi-square test.
To determine whether a promoter shows true significant enrichment, the promoter
has to contain at least one window that shows significant enrichment in at least two
92 A. Romano et al. / Molecular and Cellular Endocrinology 314 (2010) 90–100
Fig. 1. ChIP-chip: quality control, validation and prevalence of EREs. (A) Prior to ChIP-chip hybridisation, immunoprecipitated (IP) DNA fragments were amplified (linear-
amplification). As a quality check, binding of ER- to the TFF1 promoter was confirmed after each amplification round (shown for each experiment at the end of the
amplification, just prior to labelling and hybridisation). ChIP-DNA = IP DNA. Input-DNA = non-IP- chromatin amplified similarly to the ChIP-DNA. (B) ER- targets identified
by ChIP-chip and validated by standard ChIP. For all ChIP experiments, cells were treated for 50 min; control = vehicle-treated cells; E2 or 17-estradiol: 1 nM. IgG = ChIP with































ssessed (RT-PCR or semi-quantitative PCR—semiQ-PCR) after different periods of ho
RNA is significantly regulated in the indicated direction (p < 0.05 compared to ti
revalence of EREs in the promoters of the entire group (n = 904) of ER- target ge
ere scanned using a family of ERE consensus matrices (Cartharius et al., 2005).
reated samples (positive controls) and the same window or windows should not
how significant enrichment in more than one untreated sample (negative controls).
o minimise false positives, an adaptation of the Benjamini and Hochberg method
Benjamini and Hochberg, 1995) is applied to calculate false discovery rates (FDR).
Both methods showed over 50% consistency when a FDR threshold of 20% was
pplied. We compared the list of target genes obtained with the two methods with
list of already known targets (O’Lone et al., 2004). Given that at the same FDR,
ethod (ii) retrieved a larger number of known target promoters when compared
o method (i) and considering the greater robustness of a between-array approach,
ethod (ii) was used to generate the list of targets used for further analysis.
To identify our 904 promoters, we combined results using two FDR cut-off
oints. We first identified a suitable cut-off point able to retrieve as many previ-
usly found targets (O’Lone et al., 2004) as possible. Using a FDR cut-off of 20% we
dentified most known targets (i.e. CTSD, BRCA, c-Myc, ADORA1, AGT, HSPB1, LCN2)
nd only few more (TGFA, TERT) were retrieved when cut-off points with lower strin-
ency (FDR cut-offs higher than 20%) were used. Therefore, 20% FDR was fixed as
he upper limit for the stringency of our statistics. Subsequently, a low stringency
FDR 20%) was used to identify ER- targets common in the arrays of the indepen-
ent experiments (T1 and T2 or T1, T2 and P). A high stringency (FDR 5%) was used
or targets that were common in one of the T arrays and the P array, as those are
ssentially technical replicates.
The promoter regions were scanned for occurrence of EREs using the Genomatix
atInspector software (Cartharius et al., 2005) and the Genomatix transcription
actor motif database (www.genomatix.de). We also scanned promoter sequences
f a validated sub selection of ER- targets for the presence of potential tethering
omains for EREs (AP1, NFB and SP1 binding sites), using the same approach..9. Cell transfection, luciferase assay and immunocytochemistry
Plasmids used for transfection were previously described: ERE-TK-luciferase
2X ERE-TK-LUC) containing the estrogen responsive promoter-luciferase reporter
Oehler et al., 2004), was gifted by Prof Schuele. The expression vector for co-e stimulation (up to 24 h) in triplicate. Results in column signify that the considered
int zero) at one time point at least (results not shown). ND: not determined. (C)
s determined by Genomatix MatInspector (http://www.genomatix.de). Promoters
activator SRC-1 (Smith et al., 1997) and the co-repressor SMRT (Chen and Evans,
1995) were gifts from Prof O’Malley and Prof Evans, respectively. The SMRT expres-
sion plasmid used in these experiments encodes for a truncated form of the human
co-repressor SMRT (amino-acids 1032–2517) with a dominant co-repressing action
(Peterson et al., 2007). Plasmid pCNDA3.1 (Invitrogen, Life Technologies, Inc., Carls-
bad, CA) was used as empty vector (when indicated). All techniques were previously
described (Romano et al., 2007). In short, transfection was performed using the
jetPEITM reagent (Q-Biogene, Heidelberg, Germany) as recommended by the manu-
facturer. Prior to luciferase assays, cells were cultured in 2 wells of a 12-well plate
and were transfected (2 g DNA plus 3 l jetPEITM per well). Sixteen hours after
transfection, cells from the 2 wells were trypsinised, pooled and seeded into 12
wells of a 96-well plate. Eight hours after plating, treatments were applied. Each
treatment was performed in triplicate (the number of initially transfected wells
was scaled up according to the number of stimulations needed). In case of RNA iso-
lation, cells were transfected in two 25-cm2 flasks (10 g DNA plus 15 l jetPEITM per
flask) and subsequently cells were pooled and plated in 9 wells of a 12-well plate. For
immunocytofluorescence, cells were cultured on glass cover slips fixed in buffered
formaldehyde (4% paraformaldehyde in PBS), permeabilised with 0.1% Triton-X-100
in PBS and stained with the following antibodies (as indicated in the figures): goat
polyclonal C-20 against co-activator SRC-1 and sc-1609 against co-repressor NCoR
(Santa Cruz Biotechnology, CA, USA), followed by anti-goat FITC secondary anti-
body 705-095-147 (Jackson Immunoresearch/Brunschwig chemie B.V., Amsterdam,
The Netherlands); rabbit polyclonal H-300 against co-repressor SMRT (Santa Cruz
Biotechnology, CA, USA), followed by anti-rabbit FITC F005401 (DAKO, Glostrup,
Denmark). For western blot (Supplemental Figure S-1) ER- was detected with mon-
oclonal antibody F10 (Santa Cruz Biotechnology, CA, USA), whereas p300 and CBP
with rabbit A-22 and N-15 antibodies, respectively (Santa Cruz Biotechnology, CA,
USA). Mouse antibody AC-15 (Sigma–Aldrich Chemie BV, Zwijndrecht, The Nether-
lands) was used to detect -actin. HRP-conjugated rabbit anti-mouse-antibodies
(DAKO, Glostrup, Denmark) and goat-anti-rabbit-antibodies (Pierce, Aalst, Belgium)
and the super signal-R West-Femto kit (Pierce, Aalst, Belgium) were used for primary
antibody visualisation.
A. Romano et al. / Molecular and Cellular
Table 1
Number of ER- binding sites per chromosome.



























































Nimblegen: www.nimblegen.com; Genomatix transcription factor database:
ww.genomatix.de.
. Results
.1. Identification of genomic binding sites for ER-˛
ER- binding sites in gene promoters were searched genome-
ide using the estrogen responsive T47D breast cancer cells.
strogen responsiveness was shown by the expression of ER-, the
nduction of various known estrogen responsive genes (TFF1, c-Myc,
CND1) and by the induction of cell proliferation by 17-estradiol
Supplemental Figures S-1 and S2). T47D cells were incubated
ith 1 nM 17-estradiol for 50 min, which was shown to result in
aximal ER- binding to the TFF1 promoter (Carroll et al., 2005,
006; this study, results not shown). After chromatin immuno-
recipitation using an ER- antibody, two rounds of nucleic acid
mplification were performed to yield sufficient DNA for hybridis-
tion to the Nimblegen promoter arrays. In order to assure adequate
uality of the amplified DNA fragments, enrichment of the TFF1 pro-
oter was confirmed after each amplification round (Fig. 1A). Three
ndependent experiments, each consisting of a 17-estradiol and
vehicle-treated sample, were performed (T1, T2 and T3). Given
hat the hybridisation performance of the T3 samples was poor,
ata from experiment T3 were not used for subsequent analyses.
n additional sample was included (referred to as the pool, P) cre-
ted by combining equal amounts of amplified DNA material from
1, T2 and T3.
We applied robust statistical procedures (see ‘Section 2’), which
llowed us to retrieve several previously known ER- target pro-
oters (i.e. CTSD, BRCA, c-Myc, ADORA1, AGT, HSPB1, LCN2; O’Lone
t al., 2004). With this method, 904 potential ER- binding sites
ere identified in total (Supplemental Table S-I), some of whichre common to recent genome-wide screenings for ER- tar-
ets (Supplemental Table S-II). The 904 binding sites are equally
istributed over all chromosomes (Table 1), excluding the Y chro-
osome, as the T47D line is derived from a woman. Only one site
as found on chromosome Y and is not included in the list of 904
argets.Endocrinology 314 (2010) 90–100 93
3.2. ChIP-chip validation and target promoter features
To validate the findings of the ChIP-chip, standard ChIP assays
were performed using additional independent experiments (two
or more) and ER- binding was confirmed for a selection of 12
promoter regions (Fig. 1B). Enrichments were not seen for three
non-target locations (PGR gene exons 4 and 6 and chromosome
region 12p13.3).
To demonstrate that ER- binding to the promoter regions is
functional, the effect on mRNA expression was studied with RT-PCR
(Fig. 1B). The expression of most genes is induced by 17-estradiol,
with the exception of DKFZ p762E1312, which is down-regulated,
and FANCM, which does not respond despite ER- binding to its
promoter (Fig. 1B). In addition, we evaluated the transcriptional
response of six target genes for which ChIP reactions were not set-
up, CCNE2, IGF1-R, FBP-1, BCL2, MALL and CA2 (Supplemental Figure
S-3). All genes, except CA2, are induced by 17-estradiol. MALL
and CA2 are induced by OH-tamoxifen, whereas BCL2 and CCNE2
expression is reduced by OH-tamoxifen.
Binding sites for ER- are present both upstream and down-
stream of the transcription start site (TSS) and are evenly
distributed along the promoter regions with respect to the dis-
tance from the TSS (results not shown). Seventy four percent of the
904 target promoters contain an estrogen response element (ERE;
Fig. 1C), determined with the Genomatix MatInspector software.
3.3. Selective recruitment of co-regulators determines the ER-˛
mediated transcription
Both 17-estradiol and OH-tamoxifen can simultaneously up-
and down-regulate the transcription of different genes in the same
cell. To verify whether differential co-regulator recruitment (i.e.
co-activators versus co-repressors) accounts for these opposite
transcriptional responses in the same cells, we performed ChIP with
antibodies directed against ER-, co-activators p300, CBP and SRC-
1 or co-repressors SMRT and NCoR after exposing T47D cells for
50 min to 1 nM 17-estradiol or to 1 M OH-tamoxifen. These co-
regulators were selected because they are expressed in T47D cells
(Supplemental Figure S-1) and all three co-activators are efficiently
recruited at the promoter of TFF1 after 17-estradiol induction
(results not shown). It should be noted that we did not aim at iden-
tifying which specific co-regulator binds to one region, but rather
whether co-activators or co-repressors are recruited. CBP/p300 are
general mediators, which bridge the basal transcriptional machin-
ery to the ER-/co-activator complex, irrespective to which specific
protein is present (SRC1, SRC2 or SRC3; Smith et al., 1996; Vo
and Goodman, 2001). Therefore, in order to immunoprecipitate
all DNA sequences interacting with co-activators simultane-
ously, we pooled the antibodies against p300, CBP and SRC-1.
For the same reasons, we pooled co-repressor NCoR and SMRT
antibodies.
The expression of TFF1, DDX-27, ZNF-228 and ZWINT is up-
regulated by 17-estradiol and down-regulated by OH-tamoxifen
(Fig. 2), which correlates well with the recruitment of co-activators
and co-repressors, respectively. In contrast, the expression of FLNA,
SYMPK, KGFLP1 and BCL2L1 is induced by both 17-estradiol and
OH-tamoxifen (Fig. 3). In these cases, predominant recruitment
of co-activators is observed, although for some gene-promoters
a non-significant recruitment of co-repressors can be seen as
well (BCL2L1 after 17-estradiol treatment and FLNA after OH-
tamoxifen treatment). Expression of DKFZ p762E1312 is suppressed
by both 17-estradiol and OH-tamoxifen (Fig. 4A). In the pres-
ence of 17-estradiol, ER- recruits co-repressors only; however,
in the presence of OH-tamoxifen, co-activators are recruited as
well (Fig. 4A). This could be explained by the fact that OH-
tamoxifen induces the transcription of DKFZ p762E1312 at later
94 A. Romano et al. / Molecular and Cellular Endocrinology 314 (2010) 90–100
Fig. 2. Co-regulator recruitment at targets induced by 17-estradiol and repressed by OH-tamoxifen in T47D cells. (A) Transcriptional responses of the indicated target genes
(RT-PCR) after treatment with 17-estradiol, OH-tamoxifen (1 nM and 1 M, respectively) in T47D. Mean ± standard deviation (SD), n = 3. Asterisks: p < 0.05 compared to
time point zero. Expression data were reconfirmed in at least one extra independent experiment. (B) ChIP assessing binding of ER-, co-activators (p300, CBP and SRC-1) or














reated for 50 min before ChIP. (C) Quantitative evaluation (estimated by agarose-g
o-repressor (REP) antibodies. Mean ± SD; n = 2 or 3. Asterisks: p < 0.05 compared to t
xperiment. The ChIP negative control for these assays is shown in Fig. 4C.
ime points (Supplemental Figure S-3). Also in case of the tran-
cription up-regulation by 17-estradiol of EPHA4 (Fig. 4B), ER-
ecruits co-activators at the EPHA4 promoter. No recruitment of co-
egulators is observed for this gene in response to OH-tamoxifen
Fig. 4B) and its transcription is not altered, even though ER- binds
o the promoter.
.4. Differential recruitment of co-regulators determines
ell-specific transcriptional activities of ER-˛
Next we examined whether co-activators and co-repressors are
ecruited to selected ER- target genes in accordance with their
pposite transcriptional responses to estrogens in T47D breastd intensities) of chromatin enrichments after ChIP with ER-, co-activator (ACT) or
control. ChIP experiments were reconfirmed in at least one additional independent
cells versus ECC1 endometrial cancer cells (ECC1 cells are ER-
/co-regulator positive—Supplemental Figure S-1 and estrogen
responsive—Supplemental Figure S-2). In ECC1 cells, KGFLP1, DDX-
27 and FLNA are induced by 17-estradiol and OH-tamoxifen,
whereas TFF1 is induced by 17-estradiol only. ER- preferen-
tially recruits co-activators to up-regulate these genes (Fig. 5). In
contrast, the transcriptional inhibitory effects of 17-estradiol (for
BCL2L1) or OH-tamoxifen (for TFF1, BCL2L1 and EPHA4) are asso-
ciated with the recruitment of co-repressors after ER- binding
(Fig. 5). Interestingly, OH-tamoxifen and 17-estradiol reduce the
expression of BCL2L1 in ECC1, but induce it in T47D cells (Figs.
5B and 3, respectively). In contrast, the expression of DDX-27 is
induced in ECC1 and reduced in T47D cells by OH-tamoxifen (Figs.
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Fig. 3. Co-activators are recruited at genes induced by both 17-estradiol and OH-tamoxifen in T47D cells. (A) Transcriptional responses in T47D to 1 nM 17-estradiol or


















ne independent experiment. (B) ChIP assessing binding to the corresponding pr
stradiol. Tam = OH-tamoxifen. No treatment: induction with vehicle only). (C) Qua
o-repressor (REP) antibodies. Mean ± SD; n = 2 or 3. Asterisks: p < 0.05 compared to
xperiment (ChIP negative in Fig. 4C).
B and 2, respectively). These opposite transcriptional effects are
learly related to the recruitment of different co-regulatory pro-
eins in the two cell contexts: co-activators in case of induction
nd co-repressors in the case of inhibition of transcription. Ana-
ogue results are observed for EPHA4. This gene is induced by
7-estradiol in T47D cells, under which condition ER- recruits
o-activators (Fig. 4B). However, EPHA4 is not responsive to 17-
stradiol in ECC1 cells, and in this cell context, binding of ER-
o the corresponding promoter is not accompanied by further
o-regulator recruitment (Fig. 5B). The opposite is observed with
H-tamoxifen, which inhibits EPHA4 expression in ECC1 cells but
as no effect T47D cells. In T47D cells, no co-regulators are recruited
y ER- (Fig. 4B), whereas in ECC-1 cells, binding of ER- is fol-r of ER-, co-activators or co-repressors (50 min after induction start: E2 = 17-
ve evaluation of chromatin enrichments after ChIP with ER-, co-activator (ACT) or
ontrol. ChIP experiments were reconfirmed in at least one additional independent
lowed by recruitment of co-repressors (Fig. 5B). The recruitment
of distinct co-regulators at the promoters of DDX-27 and BCL2L1 in
T47D and ECC1 after induction with OH-tamoxifen was confirmed
by real-time PCR (Fig. 5D).
3.5. Over-expression of SRC-1 and SMRT alters the response of
target genes to OH-tamoxifenIf the regulation of the aforementioned genes is truly depen-
dent on co-regulators, it should be expected that, as previously
shown (Peterson et al., 2007; Smith et al., 1997), modification in
the level of some of these proteins modifies the response of the
target genes. Therefore, to confirm the association between up- or
96 A. Romano et al. / Molecular and Cellular Endocrinology 314 (2010) 90–100
Fig. 4. Co-regulator recruitment by activated ER- at DKFZ p762E1312 and EPHA4 in T47D cells. (A) On the left: transcriptional responses of the DKFZ p762E1312 gene
(repressed by both 17-estradiol—1 nM and OH-tamoxifen—1 M) in T47D (RT-PCR). Mean ± SD, n = 3. Asterisks: p < 0.05 versus time point zero. RNA data were reconfirmed
in at least one extra independent experiment. Middle: ChIP assessing binding to the DKFZ p762E1312 promoter of ER-, co-activators or co-repressors. ChIP was performed

















R-, co-activator (ACT) or co-repressor (REP) antibodies. Mean ± SD. Asterisks: p < 0
ot influenced by 1 M OH-tamoxifen (on the left; mean ± SD, n = 3. Asterisks: p < 0
xperiment. Middle and right: ChIP assay and quantitative evaluation of the ChIP ex
ersus IgG control). (C) ChIP negative control (cytogenetic location 12p13.3).
own-regulation and recruitment of co-activators or repressors,
e over-expressed co-activator SRC-1 or co-repressor SMRT by
ransient transfections in T47D and ECC1 cells (Fig. 6A). To proof
hat these transfections had significant and measurable effects,
e assessed the activity of the estrogen responsive construct
RE-TK-luciferase after co-transfection with SRC-1 or with SMRT.
s expected, SRC-1 over-expression enhances the 17-estradiol-
nduced luciferase activity, whereas SMRT reduces it (Fig. 6B).
oreover, to confirm the transfectability of T47D and ECC1 cells
e also measured GFP expression after transient transfection with
GFP expression plasmid (Supplemental Figure S-4).
Fig. 6C shows the effect of SRC-1 or SMRT over-expression
n a number of identified target genes. In T47D cells, BCL2L1rsus IgG control, n = 2 or 3. (B) EPHA4 gene is induced by 17-estradiol (1 nM) but is
sus time point zero). RNA data were reconfirmed in at least one extra independent
ents (mean ± SD based on at least two independent experiments. Asterisks: p < 0.05
transcription is normally up-regulated by OH-tamoxifen. Over-
expression of the co-activator SRC-1 enhances this effect, whereas
over-expression of the co-repressor SMRT changes OH-tamoxifen
into an inhibitor of transcription (Fig. 6C). In ECC1, BCL2L1 is nor-
mally repressed by OH-tamoxifen, but over-expression of SRC-1
changes OH-tamoxifen into an inducer of transcription.
With regard to the expression of EPHA4, over-expression of SRC-
1 in T47D cells turns OH-tamoxifen into an inducer of transcription,
whereas this gene is unresponsive under normal conditions. In
ECC1 cells, EPHA4 transcription is inhibited by OH-tamoxifen and
SRC-1 over-expression impairs this repressive activity. Also in case
of the transcriptional activation of KGFLP1 in both T47D and ECC1
cells, SMRT over-expression is sufficient to revert (in T47D cells;
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Fig. 5. mRNA level and co-regulator recruitment in ECC1 cells. (A and B) Transcriptional responses (RT-PCR and semiQ-PCR for KGFLP1) after 17-estradiol or OH-tamoxifen
stimulation (1 nM and 1 M, respectively) in ECC1 (left side of panels A and B). Mean ± SD, n = 3. Asterisks: p < 0.05 versus time point zero. RNA expression data were
reconfirmed in at least one additional independent experiment. ChIP assays (50 min of induction) showing binding of ER-, co-activators (SRC-1, CBP and p300) and co-
repressors (NCoR and SMRT) to the corresponding promoter are shown on the right of each A and B panels (E2 = 17-estradiol. Tam = OH-tamoxifen. No treatment: vehicle
only). ChIP experiments were reconfirmed in at least one additional independent experiment. (A) The transcriptional response of these genes in ECC1 (shown in panel) is
similar to the response observed in T47D cells (shown in Figs. 2A and 3A) and ChIP indicates that the same kind of co-regulators are recruited at gene promoters in the two





















esponse observed in T47D cells (shown in Figs. 2–4) and ChIP indicates that the di
ells (Figs. 2–4). (C) ChIP negative control (cytogenetic location 12p13.3). (D) Relat
DX-27 and BCL2L1 in T47D and ECC1 cells after OH-tamoxifen induction (50 min).
he direction of the mRNA regulation is indicated by the arrows. ChIP reactions w
ersus IgG control).
H-tamoxifen becomes a repressor of transcription) or impair (in
CC1 cells; OH-tamoxifen does not change gene transcription) this
esponse (Fig. 6C).
Transcription of DDX-27 is suppressed by OH-tamoxifen in T47D
nd induced in ECC1 cells. Over-expression of SRC-1 does not affect
he inhibitory action of OH-tamoxifen in T47D, but over-expression
f SMRT in ECC1 cells turns OH-tamoxifen into a repressor of tran-
cription (Fig. 6C).
The response to OH-tamoxifen of other validated genes (TFF1,
LNA, SYMPK, DFFZ p762E1312, ZWINT and ZNF-228) and the
esponses to 17-estradiol in general, were not significantly influ-
nced by modifications of the level of SRC-1 and SMRT (data
ot shown). This suggests that co-regulators, themselves or as a
onsequence of cell-specific post-translational modifications, are
romoter-specific.. Discussion
The aim of the present study was to elucidate the role of co-
egulators in (i) the opposite transcriptional actions mediated byco-regulators are recruited at gene promoters in ECC1 (shown in panel) and T47D
richments of ER-, co-activators (ACT) or co-repressors (REP) at the promoters of
moxifen induces DDX-27 and BCL2L1 in opposite directions in T47D and ECC1 cells.
easured by real-time PCR (mean ± SD based on two replicates. Asterisks: p < 0.05
ER- on different target genes and (ii) the tissue specific actions
of OH-tamoxifen (and 17-estradiol) in breast and endometrial
cancer cells. To this end, we first identified ER- target promot-
ers genome-wide by ChIP-chip and subsequently we examined
whether co-activators or co-repressors are recruited by acti-
vated ER- at the promoters of a number of newly identified
targets.
Though some past studies have focussed on the genome-wide
identification of ER- binding sites in breast cancer cell lines
(Bourdeau et al., 2008; Carroll et al., 2005, 2006; Cheng et al., 2006;
Jin et al., 2004; Kwon et al., 2007; Laganiere et al., 2005; Lin et
al., 2004, 2007a,b), none have further considered the role of co-
regulators on the transcriptional regulation of these ER- targets.
Up to now, this knowledge has been generated by means of reporter
gene assays (Peterson et al., 2007; Smith et al., 1997) or by studying
a low number of estrogen responsive genes only (Shang and Brown,
2002; Shang et al., 2000).
In the present study, we identified 904 promoters targeted by
ER- using ChIP-chip. These results were validated by standard
ChIP, by the estrogen responsiveness of the corresponding genes at
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Fig. 6. Over-expression of SRC-1 and SMRT modifies OH-tamoxifen responses. (A) Over-expression of co-activator SRC-1 and co-repressor SMRT in T47D and ECC1 cells after
transient transfection (immunocytofluorescence). Empty arrow-heads: endogenous expression level. Solid arrow-heads: over-expressing cells. (B) Induction of the ERE-TK
promoter after co-transfection of ECC1 cells with the 2X ERE-TK-LUC construct (containing the luciferase reporter) along with either the expression plasmid for co-activator
SRC-1 (increasing amounts of plasmids used for transfection) or the plasmid expressing co-repressor SMRT. Cells were transfected as described in Section 2 in 12-well plates
using 2 g of total plasmid DNA: 1 g of 2X ERE-TK-LUC combined with variable amounts (0–1 g of SRC-1). Total amount of transfected DNA was kept constant using the
empty vector. For induction (n = 3 per treatment ± SD) and luciferase assay, transfected cells were re-plated on a 96-well plate. Similar results are obtained in T47D cells
(not shown). (C) Transcriptional responses of BCL2L1, DDX-27, EPHA4 (RT-PCR) and KGFLP1 (semiQ-PCR) after stimulation with 1 M OH-tamoxifen or with vehicle only
























s described in Section 2 in 25-cm2 flask (10 g DNA) and re-plated for induction
ignificant difference (p-value < 0.05: t-test) between transfection experiments in th
he mRNA level, and by the high prevalence of EREs among target
romoters (Fig. 1).
.1. Co-regulator recruitment at target promoters determines
ene- and cell-specific responses to ER-˛ ligands
In line with previous studies (Shang and Brown, 2002; Shang et
l., 2000; Stossi et al., 2006), activated ER- binds to gene promot-
rs, recruits co-activators or co-repressors, which determine the
ubsequent transcriptional up- or down-regulation, respectively
Figs. 2–5). In one cell type, all determinants of the ER- action
like ligand concentration, level and activation of ER- and co-
egulators) are identical, except for the promoter, which therefore
ust be responsible for the recruitment of different co-regulators.
number of studies have already shed light on the role of ERE-
otifs and additional cis-regulatory elements (AP1, Sp1, NFB
inding sites) in the cell- and ligand-specific regulation of ER-
nd ER- (Klinge, 2001; Ramsey et al., 2004; Schultz et al., 2005).
he main features of the genes analysed in the present study
EREs and binding sites for additional transcription factors) are
iven in Supplemental Table S-IV. Alternatively, it is possible that
o-regulators are modified post-translationally in a cell-specific
anner, resulting in altered interactions at gene promoters in the
istinct cell contexts.NA isolation in 12-well plates. Bars indicate mean ± SD, n = 3. Asterisks indicate a
NA fold-change after OH-tamoxifen induction.
In one case only (DKFZ p762E1312), transcription repression
by OH-tamoxifen was associated with recruitment of both co-
repressors and co-activators. We explained this effect with the
ability of OH-tamoxifen to induce DKFZ p762E131 transcription at
later time points. However, it should also be noted that the dynam-
ics, the sequential and combinatorial assembly of co-activators and
co-repressors at target promoters have not been addressed in the
present investigation. Nevertheless, these events are important for
the action of nuclear receptors (Metivier et al., 2003, 2004).
Differential co-regulator recruitment also explains the opposite
transcriptional response observed at a number of target genes in
response to OH-tamoxifen (DDX-27, BCL2L1 and EPHA4) or 17-
estradiol (BCL2L1 and EPHA4) in breast cancer (T47D; Figs. 2–4)
and endometrial cancer cells (ECC1; Fig. 5). These results confirm a
previous finding based on a number of known estrogen responsive
genes (c-Myc, IGF-I, EBAG9 and CTSD; Shang and Brown, 2002). The
present study extends this mechanism of action to potentially all
ER- target genes.
To further substantiate the association between transcriptional
regulation and co-regulator recruitment, we over-expressed either
co-activator SRC-1 or co-repressor SMRT. In a number of cases,
the transcriptional response to OH-tamoxifen in T47D or ECC1
cells could be modified or inverted by over-expression of these
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The transcription of other genes in response to OH-tamoxifen
as not influenced by SRC-1 or SMRT over-expression (TFF1, FLNA,
YMPK, DFFZ p762E1312, ZWINT and ZNF-228). In some cases, as
bserved for DDX-27, the inducing action of OH-tamoxifen could
e impaired in ECC1 after over-expression of SMRT, but the oppo-
ite inhibitory action of OH-tamoxifen observed in T47D cells could
ot be changed by SRC-1 over-expression. As shown by others
Peterson et al., 2007; Yahata et al., 2001), each promoter interacts
ith a limited number of co-regulators only and therefore each co-
egulator modulates the expression of a limited number of genes.
hese events explain why co-regulators have distinct physiological
unctions (Kuang et al., 2005; Smith and O’Malley, 2004; Wang et
l., 2009; Yu et al., 2007). In our case, it is entirely possible that SRC-
cannot be efficiently recruited at the DDX-27 promoter, whereas
either SRC-1 nor SMRT can be efficiently recruited at the promoter
f other target genes, whose transcription was not influenced by
hese two co-regulators.
. Conclusions
Complex events determine the action of ER-, including his-
one modifications (Krum et al., 2008), distal and proximal
is-regulatory elements (Carroll et al., 2006; Klinge, 2001; Ramsey
t al., 2004; Schultz et al., 2005), ligand independent signalling and
ndirect DNA binding mediated by additional transcription factors.
ur results suggest that, at least for direct ER- targets, distinct
o-regulator recruitment is one of the key modulators of hormonal
esponse.
In case of important drugs like tamoxifen, ER- is necessary but
ot sufficient to mediate its actions. The direction of the hormonal
esponse is for a large part dependent on co-regulators. Aberra-
ions in the functions mediated by these proteins may lead to
ndocrine related cancers, to innate and developed drug-resistance
n breast tumours (Balmer et al., 2006; Conzen, 2008; Lonard et al.,
007) or to poor therapeutic response observed, for instance, in
ase of ovarian tumours (Perez-Gracia and Carrasco, 2002). Unrav-
lling the expression and activation patterns of co-regulators in
strogen-dependent tumours may be the next step in predicting
rug response and personalise endocrine therapies.
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